Skip to content
Back to meeting Original
Nurullah İlhan,MD· @drnurullahilhan · X·· 2 days agoScore70

DESTINY-BREAST09

Body

DESTINY-Breast09: In 61 patients with baseline brain metastases, CNS-PFS HR was 0.26 for T-DXd + pertuzumab vs THP; CNS response 51.6% vs 26.7%. Exploratory analysis in inactive/stable BMs. Impact on 1L choice? @VHIO @OncoDaily @OncoAlert #ESMO26

22 views · 1 like · 0 reposts · 0 replies

Source: Nurullah İlhan,MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.